7th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 19-21, 2026 | Boston, Massachusetts, USA
Opioid Agonist Therapy
Opioid Agonist Therapy (OAT) is a widely used treatment for opioid use disorder (OUD), where medications such as methadone or buprenorphine are used to mimic the effects of opioids in a controlled manner. OAT helps reduce withdrawal symptoms and cravings while blocking the euphoric effects of illicit opioid use. By stabilizing brain chemistry, OAT allows individuals to focus on recovery without the constant compulsion to seek out drugs. This approach has been shown to improve long-term outcomes by reducing the risk of overdose, preventing relapse, and enabling individuals to participate more fully in therapeutic interventions. OAT is often combined with counseling, support groups, and other psychosocial treatments to address the behavioral aspects of addiction.
Frederick J Goldstein
Philadelphia College of Osteopathic Medicine, United States
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
John Michael Weber
Trauma Healed Life Coach, United States
Denis Larrivee
University of Navarra, Spain
Steve Cohen
Medvesta Hypnosis Healthcare, United States
Andrew Drasen
A Vision of Hope Media, United StatesSubmit your abstract Today
Title : The storm within: Neuropsychological insights into dysregulation and substance use in the adolescent brain
Ann Marie Leonard Zabel, Curry College, United States
Title : Integrating bibliopoetry therapy and digital health technologies for inflammation management: A neuropsychosomatic perspective
Nile Stanley, University of North Florida, United States
Title : Trauma: Till death do us part
John Michael Weber, Trauma Healed Life Coach, United States
Title : Addiction and the failure of meaning-forming
Jenni Guentcheva, GTI, United States
Title : Beating the blues today
Steve Cohen, Medvesta Hypnosis Healthcare, United States
Title : Reduction of chronic neuropathic pain by a THC-CBD combination capsule: ongoing pilot study
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States